$10 Sovaldi on Sale in Bangladesh
March 12. 2015.
Incepta Pharmaceuticals has introduced a version of Gilead's hepatitis C treatment, Sovaldi, at $10 a pill in Bangladesh, Bloomberg reports. The drug sells for $1,000 a pill in the United States.
Incepta doesn’t have a license from Gilead - Bangladesh is one country, along with Thailand, Malaysia and Morocco, where Sovaldi isn’t patented - but the company is marketing the treatment at about $900 for 12 weeks, the same price as Gilead is offering its branded version of the drug in India.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
